Atlas FDA

Therascreen EGFR, RGQ, PCR Kit

FDA premarket approval P120022/S015 · decided 2017-07-24

Approval details

PMA number
P120022
Supplement
S015
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Therascreen EGFR, RGQ, PCR Kit
Generic name
Somatic gene mutation detection system
Applicant
QIAGEN GmbH
Date received
2017-06-29
Decision date
2017-07-24
Days to decision
25 days
Decision code
OK30
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hilden
Statement
Improvement to the therascreen EFGR Kit stock Internal Control (IC) Mix manufacturing process.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
QIAstat-Dx BCID GPF Plus AMR Panel (K254194)QIAGEN GmbH2026-08-06
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K254032)QIAGEN GmbH2026-03-09
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K252329)QIAGEN GmbH2025-10-22
QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory Panel Mini (K250080)QIAGEN GmbH2025-08-27
QIAstat-Dx GI Panel 2 Mini B (K250324)QIAGEN GmbH2025-02-28
QIAstat-Dx GI Panel 2 Mini B&V (K243813)QIAGEN GmbH2025-01-08
QIAstat-Dx Meningitis/Encephalitis (ME) Panel (K242256)QIAGEN GmbH2024-10-29
QIAstat-Dx Respiratory Panel Mini (K242353)QIAGEN GmbH2024-10-25